Hallelujah! What else is there to say to that? For decades the public has been gouged at the register with outrageous pharmaceutical drug costs. Why? Because the monopoly that big-pharma has enjoyed has gone unchallenged by the swamp creatures inside the beltway. Well, there’s a new sheriff in town, and those big-pharma bullies are about to get hit hard.

Newsmax has the details we are all happy to hear.

President Donald Trump will roll out dozens of initiatives that will ensure Americans have access to the best prescription drug care possible while respecting innovation, Secretary of Health and Human Services Alex Azar said Friday.

“He will be rolling out the single most comprehensive approach to making prescription drugs affordable of any president in the history of the United States,” Azar told Fox News’ “Fox and Friends.”

It’s about … wait for it … COMPETITION!

“Dozens of initiatives, smart, targeted, efficient, but still respecting innovation, still ensuring patients in America have access to the best therapies.”

The president is scheduled to roll out the program in full during an appearance at the White House Rose Garden at 2 p.m. Friday.

The first strategy will include increased competition in the drug markets, Azar said.

“What we’re going to do is make sure we’re getting rid of any gaming by these branded prescription drug companies, to make sure they’re not preventing access for new generics coming on the market and these new biosimilars, which are the generics of these really complex expensive drugs,” said Azar. “We want to get those on the market as soon as possible and so that there’s competition.”

Between Obamacare and pharmaceutical gouging, we have all been throwing good money after bad to just try to stay healthy. It looks like there is change in the wind, in the healthcare world. Thank God! And thank Trump.

Join The Conversation!

Like us on Facebook to keep pace with David Harris Jr where you'll get exclusive access to tons of great content including videos David produces.

Show / Hide comments ()